Adicet Bio Raises $87M Via Equity To Fund Development Of Non-Hodgkin's Lymphoma Candidate


Adicet Bio Inc ACET priced an underwritten public offering of 6.25 million shares at $14.00 per share, raising gross proceeds of $87.5 million.

  • The offer price represents a discount of almost 3% from the last close price of $14.49 on Tuesday.
  • Underwriters have an option to purchase up to an additional 937,500 shares. The offering will close by December 10.
  • Jefferies and Guggenheim Securities are acting as joint book-running managers. Truist Securities is acting as a passive book-runner. BTIG, H.C. Wainwright & Co., and JonesTrading are acting as co-managers.
  • Adicet will use the proceeds to fund the development of ADI-001 for NHL, completion of preclinical development & initiation of clinical development of ADI-002 for solid tumors.
  • See the offer prospectus here.
  • Related Link: Adicet Stock Rallies After Early Responses For Off-The-Shelf Drug In B-cell Non-Hodgkin's Lymphoma.
  • Price Action: ACET shares are up 2% at $14.78 during the premarket session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareFinancingOfferingsSmall CapMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!